NB BIOTICA 90 is a potent antiplatelet medication classified as a direct-acting P2Y12 inhibitor, designed to significantly lower the chances of major cardiovascular incidents, including heart attacks and strokes. This medication is particularly beneficial for individuals experiencing acute coronary syndromes (ACS) or those who have recently undergone percutaneous coronary intervention (PCI) involving stent placement. By effectively inhibiting the aggregation of platelets, NB BIOTICA 90 helps prevent the formation of harmful blood clots that could obstruct blood vessels and lead to serious health complications. The active ingredient, Ticagrelor, reversibly binds to the P2Y12 receptor on platelets, preventing their activation and subsequent clumping. This mechanism is especially important in the context of acute coronary syndromes, where prompt and reliable antiplatelet action is needed. The onset of Ticagrelor's action is rapid, making it suitable for urgent cardiovascular scenarios. Clinical studies have indicated that Ticagrelor can lead to better outcomes in ACS patients compared to older treatments. Typically, NB BIOTICA 90 is administered as 90 mg either once or twice daily, depending on medical guidance, which ensures a sustained antiplatelet effect. It is essential to take this medication precisely as directed by a healthcare professional to maintain its effectiveness and safeguard against complications like stent thrombosis. Understanding its mechanism and adhering to prescribed usage is vital for optimal therapeutic outcomes.